Clinical results include:
71% increase in energy
30% reduction in fatigue
1.6 more hours of sleep/night
31% improvement in comfort

Fibronol™ has been proven both in the laboratory and with human trials to be very safe, Fibronol LLC is not aware of any discernable side effects to Fibronol™ other than the possibility of aggravating IBS-diarrhea conditions in some individuals with Fibromyalgia. As a result, Fibronol™ may generally be taken as an adjunct to your existing treatment program (i.e., added on top of whatever else you are currently doing). However, individuals with Fibromyalgia with pre-existing IBS conditions should gradually build up their dosage levels of Fibronol™ and/or FibroBoost™ to avoid potential aggravation of their IBS symptoms and to understand their individual dosage thresholds or tolerances. Fibronol™ is manufactured in accordance with FDA approved current Good Manufacturing Practices ("cGMP").

In clinical studies Fibronol™ showed a directional dose-response and body weight relationship, i.e., higher doses for some did elicit greater increases in sleep, energy and comfort. Based on these results, individuals with FM weighing more than 175 pounds should consider supplementation of an additional 3-6 capsules/day of Fibronol™ or 2-3 capsules/day of FibroBoost™ with their regular (6 capsule) Fibronol™ dosing, in order to optimize their FM symptom management. Fibronol™ and FibroBoost® are manufactured in Vancouver, Washington, in accordance with FDA approved current Good Manufacturing Practices (“cGMP”).

*These statements have not been evaluated by the Food and Drug Administration (FDA).
Fibronol LLC products are not intended to diagnose, treat, cure or prevent any disease.